Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
February 15, 2016
This review will summarize the current standard of care; key issues that arise when treating patients with HER2-positive disease; and developments in novel therapeutics, including small-molecule inhibitors, nanoparticles, immunotherapy, and agents targeting resistance pathways.
